Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598056 | 0.85 | NAAA (0.43) | HCAR2NAAADAGLAFFAR1ABCB1 | |
| Bromide SCHEMBL7611843 | 0.80 | HCAR2 (0.39) | HCAR2NAAADAGLAFFAR1ABCB1 | |
| SCHEMBL13443127 | 0.80 | MEN1 (0.50) | MEN1KMT2AKDM4EABCB1HTR1A | |
| SCHEMBL3606812 | 0.79 | NPC1 (0.54) | HCAR2KMT2ADAGLAFFAR1KDM4E | |
| SCHEMBL2292383 | 0.78 | TP53 (0.49) | MEN1KMT2AFFAR1HTR1ADRD2 | |
| SCHEMBL17214125 | 0.77 | KDM4E (0.48) | HCAR2KDM4ECYP11B1CYP11B2 | |
| SCHEMBL3600150 | 0.77 | CYP11B1 (0.46) | HCAR2NAAAFFAR1KDM4ECYP11B1 | |
| SCHEMBL27564972 | 0.77 | TDP1 (0.47) | HCAR2MEN1KMT2ANAAAABCB1 | |
| SCHEMBL10650358 | 0.76 | HTR1A (0.50) | MEN1KMT2AFFAR1HTR1ADRD2 | |
| SCHEMBL16057371 | 0.75 | BID (0.47) | DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674825-B2 | Dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7674825-B2 | Dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7674825-B2 | Dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT | 2008-03-06 | — | — | US | disclosed |
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT | 2008-03-06 | — | — | US | disclosed |
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT | 2008-03-06 | — | — | US | disclosed |
| EP-1216223-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| CN-1390193-A | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| EP-1216223-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | Bayer Aktiengesellschaft (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019778-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | PC, GOT2, SDHA | HCAR2 28/4885MEN1 2233/4885KMT2A 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.